Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Submit a comment

Dsg2 truncation causes a severe intestinal epithelial barrier breakdown and alters microbiome and immune response
Daniela Kugelmann, Alexander García-Ponce, Nadja Thielemann, Mariya Y. Radeva, Maresa Anders, Da Eun Kang, Christian Siadjeu, Natalie Burkard, Anja K.E. Horn, Jessica Neubauer, Matthias Hiermaier, Desalegn T. Egu, Christoph Schmitz, Oliver Kurzai, Katri S. Vuopala, Outi Kuismin, Nicolas Schlegel, Jens Waschke
Daniela Kugelmann, Alexander García-Ponce, Nadja Thielemann, Mariya Y. Radeva, Maresa Anders, Da Eun Kang, Christian Siadjeu, Natalie Burkard, Anja K.E. Horn, Jessica Neubauer, Matthias Hiermaier, Desalegn T. Egu, Christoph Schmitz, Oliver Kurzai, Katri S. Vuopala, Outi Kuismin, Nicolas Schlegel, Jens Waschke
View: Text | PDF
Research In-Press Preview Cell biology Inflammation

Dsg2 truncation causes a severe intestinal epithelial barrier breakdown and alters microbiome and immune response

  • Text
  • PDF
Abstract

Inflammatory bowel diseases (IBD) including Crohn’s disease (CD) are characterized by impaired intestinal epithelial barrier (IEB) function. Alterations in the desmosomal cadherin desmoglein 2 (Dsg2) have been linked to loss of IEB and intestinal inflammation in IBD. We investigated the pathogenic impact of a cytoplasmatic-truncating mutation in the desmosomal cadherin desmoglein 2 gene (DSG2) in an IBD patient. Genetic analysis of a CD patient revealed a likely pathogenic DSG2 mutation leading to a truncated protein lacking part of the intracellular domain. Generation of an enterocyte-specific mouse model to recapitulate the human mutation resulted in a lethal intestinal barrier defect which was evident in homozygous but not in heterozygous mice. In vitro, barrier defects correlated with changes in Dsg2 mobility and upregulation of pore-forming tight junction protein claudin-2. Organoids derived from heterozygous Dsg2 truncated mice exhibited increased epithelial susceptibility to proinflammatory cytokines. Bulk RNAseq followed by gene ontology analysis in homozygous mice revealed a skewed IL17/IL23 response overlapping with transcriptional changes in patients with CD. Furthermore, 16S rRNA sequencing revealed alterations in microbiome composition in animals that carried the Dsg2 truncation. In summary, a patient-derived mutation in the DSG2 gene causing cytoplasmic truncation in homozygous state induced a lethal intestinal barrier breakdown in mice paralleled by altered gut microbiota and intestinal immune response.

Authors

Daniela Kugelmann, Alexander García-Ponce, Nadja Thielemann, Mariya Y. Radeva, Maresa Anders, Da Eun Kang, Christian Siadjeu, Natalie Burkard, Anja K.E. Horn, Jessica Neubauer, Matthias Hiermaier, Desalegn T. Egu, Christoph Schmitz, Oliver Kurzai, Katri S. Vuopala, Outi Kuismin, Nicolas Schlegel, Jens Waschke

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts